No Data
No Data
Yibai Pharmaceutical (600594.SH) plans to pay 0.066 yuan per share in 2023, excluding interest on June 7
Yibai Pharmaceutical (600594.SH) announced that the company plans to distribute a cash dividend of 0.066 per share in 2023...
Yibai Pharmaceutical (600594.SH): The product Eddy Injection was removed from the Guangdong Union's centralized procurement status of proprietary Chinese medicines such as Qingkailing
Gelonghui, May 17丨Yibai Pharmaceutical (600594.SH) announced that recently, the Guangdong Drug Trade Center issued the “Notice on Cancelling the Status of Guizhou Yibai Pharmaceutical Co., Ltd. Product Eddy Injection” to cancel the selection/alternative status of Guizhou Yibai Pharmaceutical Co., Ltd. product Eddy Injection in Guangdong according to the “Guangdong Alliance Qingkailing and Other Proprietary Chinese Medicines Centralized Volume Procurement Document (GDYJYPDL202103)” on “selected/alternative products suspended production, sales, use, import, etc. by the drug administration department”. Alliance concentrates on proprietary Chinese medicines such as Qingkailing
Express News | Yibai Pharmaceuticals: Independent Director Song Qin Resigns Due to Personal Reasons
Express News | Guangdong Drug Exchange Center cancels Guizhou Yibai Pharmaceutical Co., Ltd. product Eddy's injection selection announcement
A-share changes | First quarter losses, Yibai Pharmaceuticals fell 7%
Gelonghui, April 19 | Yibai Pharmaceutical (600594.SH) is now down 7% to 3.85 yuan. The cumulative decline over the past 6 days has exceeded 20%, with a total market value of 3.05 billion yuan. According to news, the company announced yesterday after the market that it achieved operating income of 573 million yuan in the first quarter, down 16.26% year on year; net profit to mother was -68 million yuan, changing from profit to loss year on year. Furthermore, companies and executives were penalized for production management issues.
Yibai Pharmaceuticals (600594.SH) reported first-quarter results with a net loss of 684.548 million yuan
Yibai Pharmaceutical (600594.SH) released its report for the first quarter of 2024. The company achieved operating revenue during the reporting period...
No Data